Relevance of prognostic factors in the decision-making of stem cell transplantation in Myelodysplastic Syndromes-Reference-Cited by-同舟云学术

Relevance of prognostic factors in the decision-making of stem cell transplantation in Myelodysplastic Syndromes

Published:2016-10 Issue:suppl 1 Volume:62 Page:25-28
ISSN:0104-4230
Container-title:Revista da Associação Médica Brasileira
language:
Short-container-title:Rev. Assoc. Med. Bras.

Author:

Duarte Fernando Barroso¹,Santos Talyta Ellen de Jesus dos²,Barbosa Maritza Cavalcante²,Kaufman Jacques³,Vasconcelos João Paulo de³,Lemes Romélia Pinheiro Gonçalves⁴,Rocha Francisco Dário⁵,Coutinho Diego Ferreira⁶,Zalcberg Ilana⁶,Vasconcelos Paulo Roberto Leitão de⁷

Affiliation:

1. Centro de Hematologia e Hemoterapia do Ceará, Brazil; Universidade Federal do Ceará, Brazil

2. Universidade Federal do Ceará, Brazil

3. Hospital Universitário Walter Cantídio, Brazil

4. Universidade Federal do Ceará, Brazil; Universidade Federal do Ceará, Brazil

5. Hospital Universitário Walter Cantídio, Brazil; Universidade Federal do Ceará, Brazil

6. Instituto Nacional do Câncer, Brazil

7. , Brazil

Abstract

ABSTRACT The hematopoietic stem cell transplantation (HSCT) is the only curative alternative for Myelodysplastic Syndrome (MDS), but many patients are not eligible for this treatment, as there are several limiting factors, especially in the case of patients with low-risk MDS. The aim of this study is to discuss the factors that can guide the decision-making on referring or not a patient to HSCT. Three cases of MDS, two of which were submitted to HSCT are presented. We intend to report the difficulties in referring patients with MDS to transplant and the prognostic factors that contribute to define eligibility.

Publisher

FapUNIFESP (SciELO)

Subject

General Medicine

Link

http://www.scielo.br/pdf/ramb/v62s1/0104-4230-ramb-62-s1-0025.pdf

Reference30 articles.

1. The need for additional genetic markers for MDS stratification: what does the future hold for prognostication?;Otrock ZK;Expert Rev Hematol,2013

2. BLClinical effect of point mutations in myelodysplastic syndromes;Bejar R;N Engl J Med,2011

3. Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European Leukemia Net;Malcovati L,Hellström-LindbergE,BowenD;Blood,2013

4. Clonal architecture of secondary acute myeloid leukemia;Walter MJ;N Engl J Med,2012

5. Clinical and biological implications of driver mutations in myelodysplastic syndromes;Papaemmanuil E;Blood,2013